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Abstract
Scientific evidence has established several links between metabolic and
neurocognitive dysfunction, and epidemiologic evidence has revealed an
increased risk of Alzheimer’s disease and vascular dementia in patients with
diabetes. In July 2015, the National Institute of Diabetes, Digestive, and Kidney
Diseases gathered experts from multiple clinical and scientific disciplines, in a
workshop entitled “The Intersection of Metabolic and Neurocognitive
Dysfunction”, to clarify the state-of-the-science on the mechanisms linking
metabolic dysfunction, and insulin resistance and diabetes in particular, to
neurocognitive impairment and dementia. This perspective is intended to serve
as a summary of the opinions expressed at this meeting, which focused on
identifying gaps and opportunities to advance research in this emerging area
with important public health relevance.
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Background
Emerging data have established links between systemic metabolic 
dysfunction, such as diabetes, and neurocognitive impairment, 
including dementia. The current epidemic of dementia is driven, 
at least in part, by the concurrent epidemics of obesity, insu-
lin resistance, diabetes, and metabolic syndrome. Early research 
sought to elucidate the cause(s) for the apparent role of metabolic 
dysfunction in the increased prevalence of neurocognitive dysfunc-
tion and dementia, tentatively attributed to vascular contributions 
to cognitive impairment and dementia (VCID), and Alzheimer’s 
disease (AD).
More recent research has revealed that the relationships link-
ing metabolism and brain dysfunction are bidirectional. On the 
one hand, diabetes increases risk of dementia by about two-fold, 
while on the other hand, the development of neurocognitive 
disorders has been linked to an increased risk of metabolic disease 
(Biessels et al., 2014). While the relationships linking metabolism 
and brain dysfunction in humans are more complex and more dif-
ficult to study in isolation, mouse models of isolated cerebral amy-
loidosis and cerebral amyloid angiopathy have been discovered 
to have peripheral insulin resistance (Ruiz et al., 2016).
Genetic, epigenetic, environmental, and other mechanisms (likely 
in combination) are being implicated as underpinning these 
relationships and, in some cases, with behavior acting as a dis-
ease modifier. Of particular interest, both peripheral insulin resist-
ance (the central pathophysiologic feature of type 2 diabetes) and 
“brain insulin resistance” (a much-discussed but poorly character-
ized entity) have been suggested to play important roles in neu-
rocognitive dysfunction and dementia. Insulin resistance and the 
associated metabolic dysregulation can be driven by high-fat 
(“Western”) diet, physical inactivity, and obesity, and have deleteri-
ous effects on neurocognition (Ishii & Iadecola, 2015a).
Because the pathophysiological processes that lead to meta-
bolic and neurocognitive dysfunction precede the development of 
clinical syndromes by years, early intervention and preven-
tive measures are possible and an area of intense study (Norton 
et al., 2014). Indeed, AD neuropathology is detectable more than 
10 years before the onset of the first clinical symptoms (Bateman 
et al., 2012) and pre-diabetes also precedes diabetes by years in 
most cases. There is now a focus on biomarkers and interven-
tion research at pre-disease states, as there may be a higher 
chance that diseases are modifiable at this stage and prevention 
may be attainable (Sperling et al., 2015).
Confounding the picture is evidence that diabetes worsens VCID 
and, in turn, that VCID increase the likelihood of developing 
AD pathology. Nonetheless, diabetes and dementia are complex 
diseases, with heterogeneous risk factors, underlying mecha-
nisms, and clinical expressions, often with different contributing 
co-morbidities.
In this era of precision medicine, it is imperative that we iden-
tify the various metabolic-neurocognitive phenotypes in order to 
understand the mechanisms that drive these diseases so that we can 
develop targeted therapeutic strategies to successfully manage and, 
hopefully, prevent these complex, multifactorial diseases.
In July 2015, the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) at the National Institutes of Health 
(NIH) gathered a group of cross-disciplinary scientific experts in 
Bethesda, MD for purposes of: 
(1) Reviewing the state-of-the-science;
(2) Identifying key knowledge gaps and critical unanswered 
questions; and
(3) Developing ideas for future directions to advance investi-
gation at the intersection of metabolic and neurocognitive 
dysfunction.
The meeting focused on clarifying leading candidate mechanisms 
that may explain relationships between metabolic and neurocog-
nitive dysfunction, with a special emphasis on the bidirectional 
relationships between diabetes and/or insulin resistance (either 
peripheral, central, or both) and cognitive impairment and AD 
and/or VCID. Although there has been increased attention to the 
neurodegenerative and/or vascular contributions to cognitive 
impairment and dementia (Snyder et al., 2015), it is important 
to consider the contributions of mechanisms that may not fall 
into either category as well as mechanisms that span multiple 
categories.
In this White Paper, we have attempted to survey and summarize 
the opinions among the experts in attendance with regard to the 
most likely mechanisms to investigate in order to improve our 
understanding of diseases and disorders at the interface of metab-
olism and cognition; in other words, to address the questions of 
“what do we know now?” and “what directions should be pursued 
in order to advance that knowledge?”. In so doing, we aim (a) 
to improve public health at the level of community medical care 
that considers patients within the context of their behaviors and 
environment; and (b) to inform public policy that would be 
required for a major effort toward prevention of these common 
co-morbid conditions of high societal burden.
            Amendments from Version 1
We have included 2 substantial changes: (1) we have 
revised and expanded discussion of the role of endothelial 
glucose transporter (GLUT1) abnormalities in linking chronic 
hyperglycemia with neurocognitive dysfunction in the context of 
diabetes and acknowledged that neurocognitive complications 
associated with diabetes in the context of chronic hyperglycemia 
may differ from other end organs such as the eye and (2) we 
have restructured and expanded the “Broad research needs” 
section (now “Broad research needs to advance the field”) 
to prioritize the topic themes identified and discussed at the 
workshop (and further identified by referee 2) in order to provide 
further context and development of these themes in order to 
better inform future research studies. We have also provided 
other edits to the manuscript based on input from the referees 
in order to further develop important aspects of the review that 
were underdeveloped in the initial submission (e.g., role of 
inflammation). 
See referee reports
REVISED
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Summary of current knowledge
Diabetes and neurocognitive dysfunction (including 
dementia)
The high prevalence of type 2 diabetes (~26%) and dementia 
(~11%) in individuals > 65 years old, and the increased relative 
risk of all-cause dementia (~2 to ~2.5-fold) conferred by type 2 
diabetes make understanding this connection a major public health 
imperative. Even individuals with type 2 diabetes without demen-
tia have subtle impairment in performance (a third of a standard 
deviation, compared to individuals without diabetes) in a range 
of cognitive functions, including learning and memory, process-
ing speed, and executive function across the lifespan (Biessels 
et al., 2014). These decrements in cognitive function are accompa-
nied by structural and functional brain changes, with one estimate 
attributing five years of brain aging (based on volumetric magnetic 
resonance imaging, MRI) to diabetes relative to chronological age 
and estimates in those without diabetes (Franke et al., 2013). The 
most common neuroimaging findings include modest white and 
gray matter atrophy (most pronounced in the temporal and frontal 
cortices), cerebral small vessel disease, and disrupted structural and 
functional connectivity (Biessels & Reagan, 2015). Of relevance 
to understanding pathophysiologic mechanisms linking diabetes 
and neurocognition is that some of these brain changes may be 
observed prior to the development of diabetes (Brundel et al., 2014; 
Convit et al., 2003).
The neurocognitive profile of diabetes shares features with aspects 
of cerebrovascular disease and AD. However, it is still unclear if 
the relationship between diabetes and neurocognitive dysfunction 
and dementia is due to classic AD pathology, vascular processes 
such as infarcts or vessel pathology, other pathologies less closely 
related to AD or vascular disease (e.g., impaired brain insulin sig-
naling), or some combination of these. Some have proposed that 
“all-cause” dementia be employed in order to avoid the implica-
tion that we can classify etiologies accurately based on current 
knowledge. Understanding the mechanism(s) that explain the 
neurocognitive complications of diabetes and other metabolic dis-
ease will be important if we are going to be successful in devel-
oping therapeutic targets and approaches to mitigate the effects of 
metabolic disease on the brain and cognitive function. This is espe-
cially the case if metabolic disease impacts the brain in ways that 
differ from its effects on other end organs impacted by diabetes and 
other metabolic disease.
The CNS pathology associated with metabolic disease has largely 
been characterized as a cognitive disorder with most of the research 
focused on brain regions and networks that support higher-order 
cognitive functions. Research on the central regulation of energy 
balance and peripheral metabolism, on the other hand, has almost 
exclusively focused on the hypothalamus and brainstem, brain 
regions and networks whose contributions to higher-order cogni-
tive functions may not have been fully defined. The recent appre-
ciation of the bidirectional relationship between diabetes and 
neurocognitive dysfunction/dementia presents an opportunity to 
combine efforts and resources to tackle both of these complex and 
related problems together. Cerebral amyloidosis can precede clini-
cal cognitive decline for up to 30 years, and during this early phase 
may occur in limited regions of the brain. Therefore, it is plausible 
that AD pathology (amyloid-beta or Aβ, tauopathy) may be present 
in the hypothalamus prior to the onset of cognitive symptoms, and 
that this hypothalamic pathology could disrupt homeostatic func-
tions such as energy balance and peripheral metabolism prior to the 
onset of detectable cognitive dysfunction (Ishii & Iadecola, 2015b).
Mechanisms linking diabetes to dementia
While diabetes is known to increase risk for dementia, the under-
lying mechanisms linking these conditions is less clear. Undoubt-
edly, given the well-established micro- and macro-vascular 
complications of diabetes, the least disputed mechanism of brain 
injury involves cerebrovascular disease. Indeed, it is now well-
established that diabetes, and elevation in the most frequently used 
biomarker of diabetes (hemoglobin A1c), increases the risk of 
stroke, and that stroke in turn, increases the risk of cognitive impair-
ment and dementia, including vascular dementia (Abbott et al., 
1987; Banerjee et al., 2012; Gorelick et al., 2011; Ivan et al., 2004; 
Li et al., 2012; Ramirez et al., 2015). Aside from brain infarction, the 
central pathologic feature of stroke (Arvanitakis et al., 2006a), other 
vascular and related processes in the brain plausibly play a patho-
physiologic role in relating diabetes to dementia, including white 
matter disease, breakdown of the blood brain barrier, inflammation, 
and others (Hsu et al., 2012; Shimizu et al., 2013). Also, co-morbid 
conditions to diabetes, such as hypertension, hypercholesterolemia, 
and obesity, and complications of diabetes such as myocardial 
infarction, can lead to cerebrovascular disease and dementia, either 
alone or in concert with one another (Yaffe, 2007). The published 
literature as a whole suggests about a two-fold increased risk of 
stroke in individuals with diabetes, pointing to other pathways also 
being involved in linking diabetes to dementia.
While AD pathology is often cited to be present in about two-thirds 
of patients with dementia, this estimate includes both patients with 
AD pathology alone, as well as those with both AD pathology along 
with other pathologies such as the pathology of VCID and/or other 
neurodegenerative dementias (e.g., synucleinopathy, TDP-43, etc). 
Overall, the most common form of dementia is “mixed demen-
tia”, and that mixture is most commonly one of both vascular and 
neurodegenerative pathology (Schneider et al., 2007). Links 
between diabetes and AD pathology are also reported but remain 
poorly understood. Some data from in vivo biomarker studies such 
as those using neuroimaging and cerebrospinal fluid, suggest that 
persons with diabetes have more brain atrophy, reduced glucose 
metabolism, and other changes in markers of neurodegeneration, 
including alterations in cerebrospinal fluid and phosphorylated 
tau in particular, that are in keeping with AD (Baker et al., 2011; 
Moran et al., 2015; Roberts et al., 2014). Mice with knockout of 
the insulin receptor in the brain show increased tau phosphoryla-
tion (Schubert et al., 2004). Data from postmortem brain tissue 
from elderly individuals have demonstrated the presence of some 
biochemical features reminiscent of insulin resistance in the hip-
pocampal formation of persons with AD (with and without dia-
betes) compared to cognitively normal controls, and this insulin 
resistance has been reported to be associated with pathology that 
involves both Aβ oligomers and fibrillar amyloid plaques (Talbot 
et al., 2012). Consistent with this is the report that a mouse model 
that accumulates only Aβ oligomers showed metabolic flexibility 
that remained relatively intact while another mouse model that 
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accumulated both Aβ oligomers and fibrils developed features of 
insulin resistance (Ruiz et al., 2016). A more recent postmortem 
study has shown that “brain insulin resistance” (a term in need 
of a precise definition) is associated with tau pathology in 
AD as well as other neurodegenerative tauopathies such as 
corticobasal degeneration (Yarchoan et al., 2014). Finally, some 
genetic data now suggest a link between diabetes and AD, as 
in the case of the insulin degrading enzyme gene or, more 
recently the SorCS1 gene which is thought to regulate Aβ 
metabolism (Lane et al., 2010; Lane et al., 2013). Thus, amyloido-
sis, tauopathy, typical AD pathology and/or other neurodegenera-
tive mechanisms -- as well as “brain insulin resistance” (perhaps 
even apart from peripheral diabetes per se) -- appear to play roles 
in linking diabetes to dementia, apart from the cerebrovascular 
mechanisms.
Nonetheless, neuropathological studies have largely failed to 
confirm a consistent association between diabetes and AD 
pathology. Indeed, only a few studies suggest associations with 
increased AD pathology, including in subsets of persons such as 
those who are apolipoprotein E epsilon 4 carriers (Malek-Ahmadi 
et al., 2013; Matsuzaki et al., 2010; Peila et al., 2002), but 
most studies show either no relationship or a relationship with 
decreased pathology that is modulated by antidiabetic therapies 
(Ahtiluoto et al., 2010; Alafuzoff et al., 2009; Arvanitakis et al., 
2006a; Beeri et al., 2005; Heitner & Dickson, 1997; Janson et al., 
2004; Nelson et al., 2009; Sonnen et al., 2009). There are reports 
that the clinical cognitive syndrome in diabetes is more dysex-
ecutive rather than amnestic (Arvanitakis et al., 2004; Arvanitakis 
et al., 2006b; Nandipati et al., 2012), arguing against a strong 
diabetes-AD connection. In the largest clinicopathological study 
to date of about 2,400 persons, diabetes was not associated with 
AD pathology when assessed using overall measures of AD and 
more specific measures of severity of tangle and amyloid pathol-
ogy (Abner et al., 2016). Whether some individual features of 
AD pathology (e.g., Aβ oligomer and/or fibril accumulation) play 
roles remains unclear. In summary, while an AD mechanism is less 
established (or perhaps less clinically important) than the vascular 
mechanism, further elucidation of this pathway may bring insight 
into other opportunities for treatment and prevention of neurocog-
nitive dysfunction and dementia. Along these lines, both observa-
tional studies and experimental clinical trials have examined the 
role of conventional and unconventional (e.g., intranasal) admin-
istration of anti-diabetes medications for treatment of clinical and 
pathologic AD (Beeri et al., 2008; Craft et al., 2012; Gold et al., 
2010; Watson et al., 2005).
Chronic hyperglycemia has been associated with reductions in 
endothelial glucose transporters such as GLUT1 that could lead 
to glucose deprivation and excitotoxicity, and could account for 
some of the neurocognitive complications of diabetes (Gjedde & 
Crone, 1981; Matthaei et al., 1986). This is unlike diabetic retin-
opathy, which has been associated with upregulation of GLUT1 
glucose transporter (Kumagai et al., 1996) and is another example 
of how diabetic complications in the brain may differ from other 
organ systems.
Yet other mechanisms underlying the association of diabetes 
with neurocognitive dysfunction and dementia need to be further 
explored. While not a widely accepted concept, some researchers 
suggest that some AD may even be considered a metabolic disease 
caused by insulin resistance in the brain, separate from diabetes 
(Rivera et al., 2005), raising yet again the need for an evidence-
based definition for “brain insulin resistance”. Given the range 
of effects of insulin in the brain, including neurogenesis, neurite 
outgrowth, and modulation of catecholamine release/uptake, other 
possible links between insulin resistance and dementia need to be 
considered. For examples, mice lacking insulin signaling in brain 
have been shown to have altered dopamine turnover associated 
with behavioral changes (Kleinridders et al., 2015). Downstream 
effects from insulin resistance, whether peripheral or central, could 
involve increased glucose and advanced glycation end products 
(AGEs), and alterations in adipokines (e.g., leptin) and other fac-
tors (Cherbuin et al., 2012; Holden et al., 2009; Yaffe et al., 2011). 
Inflammation-related events in the periphery and brain may be 
another important factor explaining the connection between diabe-
tes and neurocognitive dysfunction (see (De Felice & Lourenco, 
2015; Ferreira et al., 2014) for recent reviews of this topic). 
Effects of insulin and other factors, including inflammation in 
the brain, need further consideration as plausible underlying 
mechanisms linking insulin resistance, with and without diabetes/ 
pre-diabetes, to dementia.
Even in the absence of vascular and other complications, diabetes 
can alter synaptic plasticity in the mouse hippocampus resulting 
in cognitive deficits (Stranahan et al., 2008), and mice with dia-
betes are less likely to recover from stroke due to impaired neu-
roplastic mechanisms (Sweetnam et al., 2012). Ongoing studies 
in humans support the hypothesis that cognitive dysfunction in type 2 
diabetes is related to alterations in the mechanisms of cortical brain 
plasticity (Fried et al., unpublished observations). The mecha-
nisms for altered synaptic plasticity in diabetes are unclear but 
may be linked to reductions in efficacy of N-methyl-D-aspartate 
receptor (NMDAR)-dependent mechanisms of plasticity. Any 
downregulation in post-synaptic NMDARs to moderate this risk 
would consequently reduce the efficiency of long-term potentia-
tion and alter any NMDAR-dependent measures. Alterations in the 
efficacy of the mechanisms of plasticity have also been identified 
as early pathophysiologic steps in Alzheimer’s disease and these 
may thus represent another link between metabolic disorders and 
dementia.
Pathophysiology unique to diabetes and its impact on 
neurocognition
Studies of the relationships linking diabetes, insulin resistance, and 
neurocognitive dysfunction have largely focused on how peripheral 
metabolism impacts brain function. Unlike other complications of 
diabetes (e.g., neuropathy, retinopathy, nephropathy), neurocog-
nitive complications of diabetes have not clearly been demon-
strated to correlate with measures of peripheral glycemia (with the 
exception of very poor glycemic control, HbA1c > 10% and a 
potential role for glycemic variability) and there is only limited 
evidence for a modest association with other measures of periph-
eral glucose regulation (e.g., insulin concentration, insulin action, 
insulin resistance) (Geijselaers et al., 2015). It is possible that lower 
levels of hyperglycemia (i.e., HbA1c < 10%) may have detectable 
effects on neurocognitive function in adequately powered studies 
or that HbA1c levels may not reflect highly fluctuating blood glu-
cose concentrations, which could have independent deleterious 
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effects on glucose-sensitive tissues such as brain endothelium. It 
is also possible that there are central mechanisms that will better 
account for the neurocognitive dysfunction observed in diabetes and 
other metabolic disease. One promising line of research has central 
insulin and insulin-like growth factor 1 (IGF-1) in the spotlight. 
There is evidence that disrupted central insulin and IGF-1 
signaling may lead to disrupted neurotransmitter (e.g., dopamine) 
and astroglial cell function, brain endothelial cell function involved 
in formation and regulation of blood-brain barrier (BBB), mito-
chondrial metabolism and oxidative stress, regulation of the phos-
phorylation of microtubule-associated tau protein and clearance of 
Aβ and/or amyloid fibrils, cholesterol synthesis in the brain (impor-
tant for myelination and membrane function), glucose and lipid 
metabolism in select regions of the brain, and regulation of cen-
tral energy balance, which could relate to both metabolic and 
neurocognitive dysfunction (Bingham et al., 2002; Brüning et al., 
2000; Convit et al., 2003; Kleinridders et al., 2015; Liu et al., 2013; 
Montagne et al., 2015; Schubert et al., 2004; Stouffer et al., 2015; 
Suzuki et al., 2010; Suzuki et al., 2013). Restoring insulin function 
in the brain via intranasal insulin is now being tested as a poten-
tial therapeutic option for neurocognitive dysfunction in both dia-
betes and dementia separately (Claxton et al., 2015; Novak et al., 
2014) and repurposing diabetes drugs for use in dementia has 
also been proposed (Yarchoan & Arnold, 2014). However, more 
research in this area is critically needed. For example, it has been 
suggested that the reduced insulin signaling observed in aging, 
and exacerbated in AD, results from a neuroprotective mechanism 
(Steculorum et al., 2014). This view derives from evidence that 
decreased insulin signaling promotes life-extension in C. elegans 
(Kenyon et al., 1993) and that genetically induced insulin resist-
ance has positive effects on cognition in an animal model of AD 
(Killick et al., 2009). If so, then intranasal insulin treatment may 
produce short term benefits but deleterious effects in the long term. 
The apparent paradox between pathological insulin resistance and 
the benefits of acute disruption of insulin signaling is a complex 
topic requiring further research attention.
The physiological neuroendocrine mechanism(s) that may partici-
pate in the intersection between diet, obesity, diabetes, and demen-
tia is less clear; however, there are a few intriguing mechanisms 
to consider. Insulin modulates synaptic plasticity of dopamine 
neurons to regulate reward function and food intake behavior 
(Stouffer et al., 2015), as well as behaviors of anxiety and depres-
sion (Kleinridders et al., 2015) and hyperinsulinemia may lead to 
ineffective regulation of dopamine and increased food intake (Liu 
et al., 2013). It is also possible that hormonal changes that occur 
in obesity and diabetes, such as disrupted glucocorticoid func-
tion, could impact synaptic plasticity and brain function (Bocarsly 
et al., 2015). Impaired neuroplasticity itself, via a glucocorticoid-
related or other mechanism(s), could account for metabolic and 
neurocognitive dysfunction (Oberman & Pascual-Leone, 2013; 
Pascual-Leone et al., 2011; Stranahan et al., 2008; Wosiski-Kuhn 
et al., 2014). There is also evidence that corticotropin-releasing 
factor regulates cerebral amyloid accumulation along an as yet 
undefined pathway that is glucocorticoid-independent (Macauley 
et al., 2015).
Microglial dysfunction has become a central point for inves-
tigation in AD, since about one-third of genes associated with 
AD are expressed at high levels or exclusively by microglia. 
Glucocorticoids appear to impact microglia activation and the 
release of pro-inflammatory cytokines, which may result in neu-
roinflammation and cognitive dysfunction (Dey et al., 2014; Erion 
et al., 2014; Hao et al., 2016). Somewhat unexpectedly, the gut 
microbiome has been recently revealed as a potential modulator 
of physiological function of microglia, and research in other neu-
rodegenerative diseases and Parkinson Disease in particular, have 
suggested a gut-brain mechanism of disease (Erny et al., 2015).
Mechanisms linking diet, obesity, and neurocognition
There has been even less appreciation for how diet and obes-
ity may adversely impact brain function in the absence of diabe-
tes or dementia. Obesity has been associated with altered brain 
structure and function in animal models and in metabolically and 
neurologically healthy adults and children (Bocarsly et al., 2015; 
Hsu & Kanoski, 2014; Yau et al., 2014). Compared to adults 
with normal body mass index (BMI = 18.5 – 24.9), overweight 
and obese adults in midlife (ages 40–59 years) have a relative 
risk (RR) of 1.35 (overweight) and 2.04 (obese) for AD and 1.26 
(overweight) and 1.64 (obese) of any cause dementia (Anstey et al., 
2011). This association between overweight and obesity is not 
observed in late life (ages 60 years or older) at a time when weight 
loss is more common and a risk factor for dementia (Anstey et al., 
2011). Consumption of a high fat diet (HFD) can also nega-
tively impact the brain and cognitive function well before obesity 
onset (Hsu & Kanoski, 2014). Indeed, obesity can impact cogni-
tion independently from metabolic disease and diet can impact 
metabolic function and cognition independently of obesity. Recent 
data suggest that weight reduction may even improve neurocog-
nitive function (Horie et al., 2016). It will therefore be important 
to look beyond disease states to examine the influence of diet and 
obesity on neurocognitive function more generally.
Although obesity is occasionally associated with global measures 
of brain atrophy (Brooks et al., 2013; Enzinger et al., 2005; Raji 
et al., 2010) and cognitive decline, many studies suggest that execu-
tive function and learning and memory are most affected in both 
adults and children (Fitzpatrick et al., 2013; Francis & Stevenson, 
2013; Gunstad et al., 2007; Sabia et al., 2009). Corresponding with 
this neuropsychological profile, structural changes are observed 
in the parietal and prefrontal cortex (important for executive 
function), as well as the entorhinal cortex and hippocampus (impor-
tant for learning/memory) (Enzinger et al., 2005; Fotuhi et al., 
2012; Hao et al., 2016; Miller & Spencer, 2014; Pannacciulli et al., 
2006; Raji et al., 2010). These changes may be a consequence rather 
than a cause of obesity, as supported by neuroimaging data in the 
minipig animal model (Val-Laillet et al., 2011). Cerebral blood 
flow, a marker of neuronal activity, is significantly lower in the 
dorsolateral and anterior prefrontal cortex in minipigs with diet 
induced obesity compared to their lean counterparts. Likewise, 
in humans, there is reduced cortical thickness in the prefrontal, 
temporal and parietal cortex in adults but not in children (Sharkey 
et al., 2015), suggesting that structural changes occur after chronic 
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HFD, metabolic disease and/or obesity. Teasing apart these three 
factors is an important avenue for future work.
HFD and obesity are also associated with dopamine-dependent 
mesocorticolimbic-prefrontal alterations that may impact reward 
learning, motivation, and executive functions (Johnson & Kenny, 
2010; Sevgi et al., 2015; Stice et al., 2008; Sun et al., 2015; Vainik 
et al., 2013). Overweight/obese compared to healthy weight indi-
viduals show reduced change in striatal D2R binding potential in 
response to glucose ingestion (consistent with reduced dopamine 
release) and several studies have reported a negative association 
between basal metabolic index and the blood oxygen level dependent 
(BOLD) response to milkshake consumption in the dorsal striatum. 
Although BOLD does not directly measure dopamine release, the 
effect is dependent upon the Taq1a A1 polymorphism, which affects 
D2 receptor density, thus linking the BOLD response to abnormal 
D2R signaling which can also be linked to heightened impulsivity 
(Babbs et al., 2013). Along this line, there are emerging data that 
suggest specific macronutrients or combinations of macronutrients 
have selective effects on dopamine adaptations. One can speculate 
on the development of “vicious cycles” that lead to obesity, driven 
by both genetic makeup, dietary composition, and other factors.
Similar to the association between diabetes and AD, “brain insulin 
resistance” may play a key role. Insulin action directly affects 
central glucose metabolism and is posited to influence learning 
and memory by modulating synaptic plasticity, density, neuro-
transmission and adult neurogenesis. As such, intranasal adminis-
tration improves cognition in healthy individuals (Benedict et al., 
2004), raising the possibility that the reverse is also true; that is, 
decreased insulin signaling associated with sub-clinical insulin 
resistance accounts for the cognitive dysfunction observed follow-
ing a HFD or obesity in otherwise healthy individuals. Supporting 
this hypothesis, a functional type of “brain insulin resistance” has 
been associated with hypo-active responses in obese non-diabetic, 
cognitively intact, people within fronto-parietal circuits, which are 
critical for working memory (the ability to hold and manipulate 
new and old information “on-line”). Working memory is markedly 
impaired in overweight and obese individuals and insulin sensitiv-
ity mediates a negative association between BMI and response in 
the fronto-parietal circuit during a working memory task (Gonzales 
et al., 2010). Diet-induced obesity can also influence insulin resist-
ance in the hippocampus and likely elsewhere in the brain where 
insulin receptors are expressed, such as the amygdala and midbrain 
(McNay et al., 2010). Thus, metabolic alterations may impact 
brain function well before the onset of metabolic disorders, and 
weight reduction may improve both metabolic state and cognition 
(Horie et al., 2016).
Typical peripheral insulin resistance is often correlated with a 
number of other factors associated with diet-induced obesity that 
may also cause neurocognitive dysfunction. Obesity and HFD 
lead to systemic and central inflammation with elevated circulat-
ing IL-12 and IL-6, both of which have been linked to impaired 
processing speed and executive function, even independently of 
metabolic risk factors (Gregor & Hotamisligil, 2011; Thaler & 
Schwartz, 2010; Trollor et al., 2012). Thus, several groups have 
highlighted inflammation as “the pathway to cognitive impairment” 
(Miller & Spencer, 2014; Steculorum et al., 2014). Hypersecretion 
of glucocorticoids may also contribute. The hypothalamic-pituitary- 
adrenal axis, which is altered in obesity, regulates glucocorticoid 
secretion, and has in turn been associated with mood changes, 
memory impairment, and reduced hippocampal volume (MacQueen 
& Frodl, 2011; Raber, 1998).
Emerging work also suggests that diet-induced BBB disrup-
tion may provide a mechanistic link involving diet, obesity and 
hippocampal-dependent cognitive functions (Hsu & Kanoski, 
2014). Rats fed a HFD for 90 days show decreased expression of 
BBB tight junction proteins and the presence of sodium fluorescin, 
a fluorescent-tagged molecule normally excluded from the brain 
by the BBB and choroid plexus, was found in the hippocampus 
but not in the prefrontal cortex or striatum (Kanoski et al., 2010). 
More recently, Davidson and colleagues found sodium fluorescin 
in the hippocampus of rats that failed to show a reversal of diet-
induced impairments in hippocampal-dependent tasks upon HFD 
discontinuation, while rats demonstrating recovery of function did 
not (Davidson et al., 2012). Some evidence indicates that BBB 
integrity may influence learning and memory by affecting the 
passage of nutrients and neuroendocrine signals such as insulin, 
leptin and ghrelin from the periphery to the brain.
Neurocognitive dysfunction affecting food intake behavior 
and obesity
Many of the brain adaptations produced by diet, obesity and 
metabolic dysfunction lead to neurocognitive and behavioral 
changes that may confer additional risk for obesity (Higgs et al., 
2012; Higgs, 2015a; Higgs, 2015b; Sellbom & Gunstad, 2012; 
Vainik et al., 2013), leading to what has been described as a 
“vicious cycle of obesity, metabolic disease, and cognitive decline” 
(Davidson et al., 2014). Insensitivity to satiety can disrupt habitu-
ation or the drop in appetitive responses to foods that accompany 
eating and there is evidence that the hippocampus plays a role 
(Small et al., 2001). Work in rodents has also focused on the role 
of the hippocampus in sensing the internal state. In an associative 
learning model, diet-induced damage to the hippocampus may 
disrupt the ability of interoceptive satiety states to serve as contex-
tual stimuli signaling that a food is not rewarding in a sated state 
(Davidson et al., 2014). This, in turn, leads to positive energy bal-
ance by promoting eating in the absence of hunger.
The decreased responses in fronto-parietal circuits and corre-
sponding executive function impairments have long been impli-
cated in inhibitory control of feeding behavior (Alonso-Alonso & 
Pascual-Leone, 2007; Le et al., 2006). Adaptations in these circuits 
may therefore further promote overeating, especially in the modern 
food environment where self-control is especially taxed. In addition, 
decisions to eat depend upon multiple interacting factors besides 
hunger and hedonics. Habits, time of day, heath concerns, peer 
pressure, and stress are amongst the other important modulators. 
The prefrontal cortex is critical for integrating these factors so that 
long-term goals can override hedonic and homeostatic signals.
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Thus, while strong evidence links obesity to brain dysfunction, the 
extent to which this arises directly from adiposity, diet, metabolic 
dysfunction, or other factors is incompletely understood and future 
research in this area is needed.
Some research areas in need of increased attention
Early development
The role of early development, in particular, appears to be critical 
in understanding the link between obesity, metabolic disease, 
and neurocognitive dysfunction. Maternal obesity and metabolic 
disease, and diet during pregnancy may impact the child in utero 
and lead to a greater risk for childhood obesity, metabolic dys-
function, and neurodevelopmental disruption (Linder et al., 2015; 
Rivera et al., 2015). High-fat feeding of pregnant and nursing mice 
has been shown to have important effects of hypothalamic neu-
rocircuit formation that impacts adult brain function (Vogt et al., 
2014). Intervention in early development is critical as there is now 
evidence that dysregulated metabolic function and obesity lead to 
detectable brain and cognitive changes in young children, may dis-
rupt academic performance, and could lead to challenges in transi-
tioning to independence and successful adulthood (Mauras et al., 
2015; Mazaika et al., 2016; Semenkovich et al., 2015; Yau et al., 
2012; Yau et al., 2014).
Type 1 diabetes
While the association between type 2 diabetes and dementia has 
been reported for some time, there has been less attention paid 
to whether type 1 diabetes may be associated with dementia. We 
now know that childhood-onset type 1 diabetes leads to detectable 
brain and cognitive changes in early life through middle adulthood 
(Mauras et al., 2015; Mazaika et al., 2016; Nunley et al., 2015a; 
Nunley et al., 2015b; Ryan et al., 2015; Semenkovich et al., 2015), 
including changes in brain fMRI (Musen et al., 2008). It will be 
important to understand how glycemic dysregulation over the 
lifecourse impacts neurocognitive function, disease management, 
and risk for dementia. Iatrogenic hypoglycemia may play some 
role(s) that remain to be clarified.
Relationships among central and peripheral insulin signaling 
and metabolism
A complex and confusing literature has already accumulated 
wherein no obvious single, simple model adequately explains the 
bidirectional relationships linking central and peripheral insulin 
signaling and metabolism. Because of this, we are not attempt-
ing to summarize all that literature here. However, we would 
refer the reader to Ishii & Iadecola (2015b), (Ruiz et al., 2016), 
and (Knight et al., 2016). The former provides an outstanding 
summary of the primary and secondary involvement of the 
hypothalamus in AD, while the latter two provide examples of the 
largely unappreciated metabolic dysfunction present in standard 
models of AD pathology and the unexpected effects that can result 
when either the AD pathology, the metabolic pathology, or both, 
are manipulated.
Broad research needs to advance the field
The workshop concluded with discussion of the research pre-
sented and reviewed above in order to identify research needs to 
move the field forward. There were several research needs identi-
fied at the workshop; however, there were three major themes that 
emerged:
1.  An urgent need for prioritizing best candidate mechanisms 
and defining constructs: Despite a relatively high incidence of 
obesity, diabetes, and dementia and extensive research into the 
underlying mechanisms of these diseases independently from 
one another, there is still a dearth of research at the intersection 
of these diseases. Advancing research in this area is hampered 
by the lack of consensus on which of the candidate mechanisms 
that explain the intersection of obesity, diabetes, and dementia, 
are most promising to pursue for future research studies. There 
is also a lack of consensus on how best to define and meas-
ure these diseases and/or the aspects of these diseases that may 
explain their comorbidity. For example, there is a need for an 
operational definition for “brain insulin resistance” in order to 
inform decisions about which tools can be leveraged or devel-
oped for future research studies to elucidate the potential con-
tribution of “brain insulin resistance” to cognitive impairment 
and peripheral metabolic dysfunction.
2.  Experimental studies: There is a crucial role for tissue-
based and non-human animals studies to help us elucidate the 
pathogenesis and treatment of obesity, diabetes, and dementia, 
including the capability for in depth measurement of central 
and peripheral processes of critical importance to obesity, dia-
betes, and dementia at temporal and spatial scales not possible 
in human studies; however, these studies also have limitations, 
such as questionable translational potential to human studies. It 
is a challenge to the researchers that will be advancing this field 
to address the limitations of their models by developing better 
models and alternative methods to improve generalizability for 
the human studies informed by these experimental studies.
3.  Human studies and research collaborations: It will be 
important to develop a common vocabulary for defining and 
categorizing obesity, diabetes, and dementia, and the critical 
mechanisms that underlie the links between these diseases. It 
will also be crucial for researchers to interact and collaborate 
across disciplines from fields such as basic and systems biol-
ogy, endocrinology, neuroscience and behavioral science, and 
computational and engineering sciences in order to advance 
research in this inherently multidisciplinary area requiring the 
use of multidimensional research approaches and tools. Future 
research will require more sensitive and specific instruments 
as well as tests to assess the important contributing factors 
that explain the neurocognitive complications associated with 
obesity and diabetes (especially in the initial stages of these 
diseases) in order to inform the development of treatment 
protocols that will prevent or mitigate these complications. It 
will also be critical to evaluate a range of cognitive and brain 
outcomes using a diverse set of tools and measures, which may 
be differentially impacted by the various factors associated 
with neurocognitive dysfunction in the context of metabolic 
disease (e.g., high-fat diet, visceral adiposity, hyperglycemia, 
insulin resistance). A holistic vision would allow the research 
community to identify a range of comorbid and confounding 
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factors associated with obesity and diabetes from vascu-
lar risk factors and inflammation to important psychiatric 
conditions, such as depression. Finally, it is unclear which inter-
ventions will lead to the prevention and/or mitigation of the 
neurocognitive complications associated with obesity and dia-
betes whether it be repurposed diabetes drugs; diet, weight loss, 
and exercise interventions; or novel therapeutic approaches such 
as neuromodulatory or other therapies. This is another research 
avenue in need of increased attention.
For additional identified broad research needs identified at the 
workshop, see Supplementary File 2: Other Broad Research 
Needs.
Future directions
Now is a critical period for research in the field of metabolic 
and neurocognitive dysfunction. Major complementary efforts, 
including the Brain Research Through Advancing Innovative 
Neurotechnologies (BRAIN) initiative, the National Plan to 
Address Alzheimer’s Disease (NAPA), the Big Data to Knowledge 
(BD2K) initiative, and the Precision Medicine Initiative (PMI), 
will provide the financial support, tools, and scientific communi-
ties that are poised to substantially advance mechanistic research 
linking metabolic disease and neurocognitive dysfunction within 
the next dozen or so years. The scientific challenge here is to 
determine the mechanism(s) that explain the interactions between 
metabolism, the brain, and neurocognitive dysfunction, in order to 
identify methods for early detection of risk for metabolic and neu-
rocognitive dysfunction and potential strategies and critical periods 
for prevention, mitigation, and intervention for these diseases. 
Figure 1 illustrates the most plausible biological mechanisms that 
may explain the bidirectional relationship between metabolic and 
neurocognitive dysfunction. These include mechanisms at the 
molecular, cellular, organ and tissue-based, and systemic levels, 
which may lead to metabolic and neurcognitive dysregulation that 
underlies disease processes contributing to obesity, insulin resist-
ance, prediabetes, type 2 diabetes, and dementia (including VCID, 
VaD, AD, and others). In addition, these factors may be modified 
by other biological, behavioral, and environmental factors, which 
may be targets to optimize health outcomes. Public policy can 
serve as the ultimate modifier of these various risk factors, and will 
determine the success of the major effort required to prevent these 
common co-morbid diseases that are increasingly likely to burden 
our aging population.
An important step toward that goal is to take a highly heterogeneous 
group of individuals with metabolic and neurocognitive dysfunc-
tion and begin to cluster them into more homogeneous subgroups 
based on detailed clinical, metabolic, and neurocognitive data. This 
includes the need for more human brain specimens from individu-
als with good physiological characterization regarding diabetes, 
metabolic function, and neurocognitive function throughout the 
lifespan. This would allow preclinical researchers to test poten-
tial mechanisms based on distinct, relevant metabolic and neu-
rocognitive abnormalities and develop prevention and treatment 
strategies targeting these phenotypes. Animal models will be an 
important contribution to these preclinical studies and should have 
comparable abnormalities in conserved domains compared to 
humans. For example, in rodents, it is reasonable to assume that learn-
ing and memory functions are somewhat comparable to humans, but 
it is unlikely that executive functions and decision-making (and the 
neural circuits that support these functions) are similar between 
species. Finally, a more homogeneous cluster of individuals with 
shared metabolic and neurocognitive resilience, risk or disease fac-
tors are allocated to targeted prevention and intervention efforts 
based on shared mechanisms to optimize prevention, mitigation, 
and treatment of the neurocognitive complications of diabetes and 
related metabolic dysfunction. In many ways, we already have 
the tools and technologies in place to perform deep phenotyp-
ing to guide future efforts for targeted, individualized therapies. 
Recently, it was discovered based on genetic analyses, that type 2 
diabetes may in fact consists of 3 subtypes and that one specific 
subtype appears to be associated with neurological disease (Li 
et al., 2015). This type 2 diabetes subtype was also associated with 
cardiovascular disease, but not diabetic retinopathy or nephropathy, 
which implies that the mechanisms for neurocognitive complica-
tions of diabetes differ from complications in other end organs. 
There are related efforts, methods, and tools in development that 
could be leveraged for further discovery into the mechanisms at the 
interface of metabolic and neurocognitive function, including in 
the areas of neuroimaging (Yeo et al., 2016) and neuroimaging 
genetics (Thompson et al., 2014), web-based cognitive testing 
(Germine et al., 2012), and individualized neural and physiological 
phenotyping over time (Poldrack et al., 2015; Wang et al., 2015; 
Yeo et al., 2016).
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Figure 1. Possible mechanisms explaining  the bidirectional  relationship between metabolic and neurocognitive dysfunction. The 
most plausible biological mechanisms (middle panel: molecular, cellular, organ and tissue-based, systemic) are shown that may explain 
the bidirectional relationship between metabolic (left panel: obesity, insulin resistance, prediabetes, type 2 diabetes) and neurocognitive 
dysfunction, including dementia (right panel: e.g., VCID, VaD, AD, other). Genetic and epigenetic mechanisms (not represented in the figure) 
likely trigger the pathophysiological processes underlying metabolic and neurocognitive dysfunction (represented by the innermost circle), 
and these disease processes, in turn, may be modified by other factors (listed under the “policy” umbrella), which may be targets to maximize 
health outcomes and behaviors. Finally, public policy (including health policy and health care management) is the societal tool that can serve 
as the ultimate modifier of these various risk factors, and will determine the success of the major effort required to prevent these common 
co-morbid diseases that are increasingly likely to burden our aging population.
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The authors offer a balanced review regarding the relationship between cognitive decline and insulin
resistance. They cover a majority of important studies, providing excellent insights into our current
knowledge, and more importantly gaps in definition, pathophysiology, and prevention and treatment of
cognitive impairment related to diabetes.
One of the strongest parts of the paper is highlighting a probable reciprocal cause and effect relation
between diabetes, leading to the cognitive decline, and neurodegenerative lesions in the brain, resulting
in central insulin resistance. On the one hand, diabetes can contribute to dementia via a range of
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in central insulin resistance. On the one hand, diabetes can contribute to dementia via a range of
mechanisms, including vascular components , peripheral and central inflammatory response via
activation of microglia , change in the blood brain barrier ,  and neurostructural changes, both in white
and gray matter . On the other hand, neurodegenerative changes, such as amyloid deposition in the
brain, especially in the hypothalamus , may lead to insulin resistance and probably a central type of
metabolic disorders and diabetes. This idea opens a new window in organized research for dementia and
diabetes and at the same time underlines an urgent need to clarify the priorities in these vital fields.
This paper provides a long list of possible gaps and plans for further studies; however, some themes
stand out:
An urgent need for definitions, and collaborations: Despite a relatively high incidence of
diabetes and dementia and not surprisingly extensive research in these conditions, still no
worldwide consensus exists on definitions, inclusion and exclusion criteria and clarity on some key
words. This can be partially explained by focused research in diabetes and dementia, conducted in
different disciplines in parallel and sometimes opposite directions. Considering diabetes as a
systemic disease, affecting almost each and every part of human body, and cognitive decline, as a
condition with a wide range of etiologies, and presentations, it is a high time to look at these
common disorders in a more holistic, multi-dimensional vision and create data banks, including all
available data and use similar definitions, and common vocabularies. Such national/international
data banks may provide a better insight into epidemiology, pathophysiology, prevention,  and
treatment of dementia and diabetes and at the same time can save our limited health resources.
 
Experimental studies: Animal studies play a significant role on our current knowledge in
medicine. Despite their undeniable advantages in the evaluation of pathogenesis and treatment of
several diseases, they still suffer from specific limitations, mainly due to high costs as well as the
selection of the most appropriate animals. A similar significant gap can also be seen in animal
studies of dementia and diabetes, using different animals, with limited sample sizes and lack of
enough controls. Therefore, it may be worthwhile creating national/ international data banks for
animal samples from both sexes with or without diseases, covering all possible aspects of animal
studies, from behavioral and cognitive abilities to imaging and pathology. Such data banks could
facilitate multidiscipline studies, save our resources and more importantly save on the number of
sacrifized animals. This is an important step towards a better understanding of the pathogenesis of
dementia and diabetes, and even starting new trials based on the underlying causes, such as
anti-inflammatory medications.
 
Human studies: Using a common vocabulary in definition and categorization of diabetes and
dementia, having national / international animal banks and finally a multidimensional approach
toward such diseases with multiple and reciprocal presentations and etiologies may lead to optimal
human studies and the creation of national/international human data banks. Undoubtedly, we need
to provide more sensitive and specific instruments as well as tests to assess diabetes in the first
stages and at the same time evaluate a range of cognitive abilities from executive functions, which
is more common in vascular cognitive impairment, to memory abilities. In addition, such holistic
vision can identify a range of comorbid and confounding disabilities in diabetes, from obesity and
vascular diseases to important psychiatric conditions, such as depression. Finally, there is a need
for designing multidiscipline studies to assess epidemiological aspects of dementia and diabetes,
public health impact and practical clinical trials. Such studies can provide a great chance to detect
diseases in pre-symptomatic phases and follow them longitudinally.   Multicenter trials with factorial
design, using a combination of lifestyle modifications and medical intervention to diagnose as well
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design, using a combination of lifestyle modifications and medical intervention to diagnose as well
as prevent/ treat diabetes and dementia would have paramount of importance in each and every
community worldwide.
In summary, Stoeckel and colleagues highlight a significant gap of knowledge and consequently
appropriate management, definitions, pathogenesis and treatment of dementia and diabetes. A
combination of several comorbid and confounding factors and at the same time a possible bi-directional
relationship between these common conditions emphasizes an urgent need for a more holistic
multidimensional vision to tackle diabetes and dementia together.
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This rather comprehensive review of the connections between the metabolic syndrome associated with
Type-2 diabetes mellitus (T2DM) and cognitive impairment was inspired by a workshop held by the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).  The article is so thorough and
well organized that one assumes the proceedings of that meeting must have been only the starting point
and that the thoughts and opinions arising from that brainstorming session have been embellished with
considerable diligence and reflection here.
 
Most of the points covered in this “white paper” are well reasoned and well researched.  And all the topics
represent elements of pathology and pathogenesis that will be key to any faithful attempt to understand
the intersection between T2DM, dementia, and milder forms of cognitive impairment.  Other authors have
often succumbed to the temptation to focus on Alzheimer’s disease (AD) as the tag-word for these
discussions, but one of the triumphs of this review is its more general consideration of dementia and
sub-demented deficiencies as per their connections to energy substrates, both in the central nervous
system and peripherally.  Indeed, the authors highlight a consideration that seems to be gaining in
prominence and frequency in discussions of AD itself:  the fact that heterogeneity—especially within
certain classifications of age, gender, and genetics—suggests not only multiple routes to AD, but also
multiple disease endpoints.  Particularly within the “oldest-old” populations, APOE4-negative individuals,
and high-risk populations such as military veterans, classic AD pathology correlates rather loosely with
cognition.  To their credit, the authors discuss the possibility that metabolic derangement may yet be
shown to be the driving force for at least some of these cases:
 
"[I]t is still unclear if the relationship between diabetes and neurocognitive dysfunction and dementia is
due to classic AD pathology, vascular processes such as infarcts or vessel pathology, other pathologies
less closely related to AD or vascular disease (e.g., impaired brain insulin signaling), or some combination
of these. Some have proposed that ‘all-cause’ dementia be employed in order to avoid the implication that
we can classify etiologies accurately based on current knowledge."
 
Another important point made here regards the direction of causality.  Hypotheses inspired by the earliest
1,2,3
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Another important point made here regards the direction of causality.  Hypotheses inspired by the earliest
epidemiological links between dementia and T2DM presumed that complications of the latter drive the
neuropathologies (mostly, those related to protein aggregation) that underlie AD and related dementias. 
But a more accurate picture of the relevant events in AD progression has been afforded—largely through
advances in neuroimaging tools—and this insight sets the stage for researchers to now say,
 
"…the pathophysiological processes that lead to metabolic and neurocognitive dysfunction precede the
development of clinical syndromes by years…. Indeed, AD neuropathology is detectable more than 10
years before the onset of the first clinical symptoms (Bateman et al., 2012) and pre-diabetes also
precedes diabetes by years in most cases."
 
In fact, data indicate that changes in amyloid β-peptide (Aβ) precede reductions in cerebral glucose
utilization, the latter of which may be an important index of metabolic syndrome (below).  Supported by
evidence from animal models, emerging trends in hypothesis-building include the supposition that CNS
accumulation of Aβ, and perhaps other elements of neurodegeneration, are sufficient to perturb peripheral
metabolism.  This allows consideration of the possibility that correlations between cognitive impairment
and cortical amyloid burden are so capricious because an important modulatory (or even instigating)
factor is the accumulation of Aβ in subcortical regions:
 
"Therefore, it is plausible that AD pathology (amyloid-beta or Aβ, tauopathy) may be present in the
hypothalamus prior to the onset of cognitive symptoms, and that this hypothalamic pathology could
disrupt homeostatic functions such as energy balance and peripheral metabolism prior to the onset of
detectable cognitive dysfunction (Ishii & Iadecola, 2015b)."
 
It is also encouraging to see the inclusion of information on effects of obesity and diet that appear to be
independent of glycemic regulation.  This is an intriguing body of data, considering the untoward effects of
high-fat diets in rodents vis-à-vis the benefits that ketogenic diets and their mimics seem to have in
humans .  It seems that metabolic impacts on brain health could benefit from better understanding of the
effects that are brought to bear by shifts between the prominent energy-substrate molecules, perhaps
through impacts on such substances that also impact neurotransmitter pools, such as glutamate and
glutamine.  And it might be productive here to consider hypotheses regarding the finding that obesity in
midlife is correlated with dementia manifest decades later , at a time when weight  may be moreloss
common.
 
For all the salient points made in this white paper, the authors still find themselves perpetuating a
conventional assumption that seems shortsighted in light of a substantial body of evidence; this is all the
more disappointing because they consider what the implications would be “if metabolic disease impacts
the brain in ways that differ from its effects on other end organs impacted by diabetes and other metabolic
disease.”  This is almost certainly the case.  The traditional view that elevated glucose in the blood must,
by necessity, produce elevated glucose in the brain ignores the existence of the blood-brain barrier
(BBB); very little glucose can enter the cerebrum, or most other regions of the CNS, without regulated
transport, the bulk of which is handled by glucose transporter 1 (GLUT1).  Thus, it was quite surprising to
read a major conclusion in the paper that seems to have been based primarily on a single publication, and
moreover, one devoted not to the brain but to the retina: 
 
"Diabetes is associated with upregulation of the GLUT1 glucose transporter (Kumagai et al., 1996);
glucose provides the original source of glutamate in the brain (Bradford & Thomas, 1969), and chronic
hyperglycemia may thus lead to excessive glutamate and increased risk of excitotoxicity."
 
This is subject to criticism on two counts:  1) Several studies show that AD and hyperglycemia are both
1
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This is subject to criticism on two counts:  1) Several studies show that AD and hyperglycemia are both
associated with  in endothelial glucose transporters, likely reflecting—at least in the latter—areductions
reactive feedback inhibition; this probably contributes to the diminished 2-deoxyglucose accumulation in
both disorders.  2) Excitotoxicity is more likely to be a consequence of glucose deprivation; this is a
well-established relationship , whereas the claim that high glucose elevates glutamate release is
tenuous and unsupported by citations.  Publications documenting a diminution of GLUT1 levels in
hyperglycemia and/or the converse, an elevation in hypoglycemia, comprise an overwhelming body of
evidence .  The authors later provide some evidence suggesting effects on the BBB from metabolic
abnormalities in rat models, particularly those brought on by diet, but data in humans is spotty and of
unclear relevance to glucose delivery. 
 
Less serious or less consequential issues arose with regard to a few other elements in the paper:
 
"Unlike other complications of diabetes…, neurocognitive complications of diabetes have not clearly been
demonstrated to correlate with measures of peripheral glycemia (with the exception of very poor glycemic
control, HbA1c > 10% and a potential role for glycemic variability) and there is only limited evidence for a
modest association with other measures of peripheral glucose regulation…."
 
Why would it be necessary—or indeed, even helpful—to exclude HbA1c levels and glycemic control from
the calculus?  Which indices of peripheral glycemia would be more justifiable?  To be sure, 10% is a quite
high level for HbA1c, but lower levels might show a detectable effect in an adequately powered study. 
Moreover, HbA1c might not change dramatically under conditions of highly fluctuating blood-glucose
concentrations, and yet such wild swings could easily produce intolerable strains on glucose-sensitive
tissues—including brain endothelium—simply by virtue of their volatility.
 
The authors are to be applauded for their mention (however brief) of the apparent paradox between the ill
effects of pathological insulin resistance versus the benefits of experimentally interrupting insulin
signaling, at least in .  It should be noted that similar benefits (e.g., on live span) accrue inC. elegans
mammals from inhibition of signaling for insulin-like growth factor (IGF), and  have only oneC. elegans
peptide to accomplish the roles of both insulin and IGF.  Nevertheless, the conundrum is one that has
vexed experimental gerontologists for decades, owing in part to the similar benefits afforded by attention
of the insulin/IGF signaling (IIS) pathway and by dietary restriction, the latter of which certainly reduces
overall insulin production.  One should not expect the authors to have cracked this tough nut, but
important rumination might result from a slightly more complete discussion of the differences between
reactive (feedback-mediated) insulin resistance and the proactive sort effected by empirical manipulation
of IIS. 
 
Also given short shrift here is the undeniable connection of inflammation to both metabolic syndrome and
neurocognitive disorders.  This is obviously an underappreciated link that deserves greater attention
among scientists seeking to synthesize these fields; reviewers of grants and papers continue to express
befuddlement when the topic of neuroinflammation is broached in this context.  Given the overwhelming
evidence for inflammation-related events in the etiologies of both T2DM and AD, it is almost certain to
contribute to their coincidence.  In fact, compelling evidence has supported just this sort of causal
involvement in animal models .  The authors have included the word “inflammation,” distributed diffusely
in the paper; perhaps it would create the appropriate emphasis if some of these references were
consolidated in one or two paragraphs along with more specific information, e.g., the seminal role of IKK2
in insulin resistance  and Aβ effects . 
 
Finally, the paper’s conclusion with “Some broad research needs” is doubtlessly faithful to the output of
the workshop’s deliberations, but many of the points outlined in this list come across as rather vague. 
3,4
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the workshop’s deliberations, but many of the points outlined in this list come across as rather vague. 
Without further elaboration, it is not clear what gaps in knowledge some of them would address.  One
wonders if several could be combined and embellished with a bit more elaboration. 
 
In its overall contribution, this white paper provides a very useful and much-needed synthesis of data and
concepts regarding the connections between cognition and metabolic derangement.  Modifiable elements
of lifestyle and environment have recently emerged as major considerations in the prevention of
dementia.  Stoeckel have enhanced the conversation by broadening it to other categories ofet al. 
cognitive impairment.  In addition, they largely succeeded in summarizing the current state of fields that
can seem disparate, and they highlight opportunities to draw these fields closer.
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We appreciate that Dr. Barger felt this review was “so thorough and well organized that one
assumes the proceedings of that meeting must have been only the starting point and that the
thoughts and opinions arising from that brainstorming session have been embellished with
considerable diligence and reflection here.”  We also thank the referee for concluding that “In its
overall contribution, this white paper provides a very useful and much-needed synthesis of data
and concepts regarding the connections between cognition and metabolic derangement. 
Modifiable elements of lifestyle and environment have recently emerged as major considerations in
the prevention of dementia.  Stoeckel have enhanced the conversation by broadening it toet al. 
other categories of cognitive impairment.  In addition, they largely succeeded in summarizing the
current state of fields that can seem disparate, and they highlight opportunities to draw these fields
close”.
 
: “It is also encouraging to see the inclusion of information on effects of obesity and diet thatPoint 1
appear to be independent of glycemic regulation.  This is an intriguing body of data, considering
the untoward effects of high-fat diets in rodents vis-à-vis the benefits that ketogenic diets and their
mimics seem to have in humans .  It seems that metabolic impacts on brain health could benefit
from better understanding of the effects that are brought to bear by shifts between the prominent
energy-substrate molecules, perhaps through impacts on such substances that also impact
neurotransmitter pools, such as glutamate and glutamine.  And it might be productive here to
consider hypotheses regarding the finding that obesity in midlife is correlated with dementia
manifest decades later , at a time when weight  may be more common.”loss
 
: Text modified to make this important point clear (see p. 6, paragraph 1). “Compared toResponse
adults with normal body mass index (BMI = 18.5 – 24.9), overweight and obese adults in midlife
(ages 40-59 years) have a relative risk (RR) of 1.35 (overweight) and 2.04 (obese) for AD and 1.26
(overweight) and 1.64 (obese) of any cause dementia (Anstey et al. 2011). This association
between overweight and obesity is not observed in late life (ages 60 years or older) at a time when
weight loss is more common and a risk factor for dementia (Anstey et al. 2011).”
 
: “For all the salient points made in this white paper, the authors still find themselvesPoint 2
perpetuating a conventional assumption that seems shortsighted in light of a substantial body of
evidence; this is all the more disappointing because they consider what the implications would be
“if metabolic disease impacts the brain in ways that differ from its effects on other end organs
impacted by diabetes and other metabolic disease.”  This is almost certainly the case.  The
traditional view that elevated glucose in the blood must, by necessity, produce elevated glucose in
the brain ignores the existence of the blood-brain barrier (BBB); very little glucose can enter the
cerebrum, or most other regions of the CNS, without regulated transport, the bulk of which is
handled by glucose transporter 1 (GLUT1).  Thus, it was quite surprising to read a major
1
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handled by glucose transporter 1 (GLUT1).  Thus, it was quite surprising to read a major
conclusion in the paper that seems to have been based primarily on a single publication, and
moreover, one devoted not to the brain but to the retina: 
 
"Diabetes is associated with upregulation of the GLUT1 glucose transporter (Kumagai et al., 1996);
glucose provides the original source of glutamate in the brain (Bradford & Thomas, 1969), and
chronic hyperglycemia may thus lead to excessive glutamate and increased risk of excitotoxicity."
 
This is subject to criticism on two counts:  1) Several studies show that AD and hyperglycemia are
both associated with  in endothelial glucose transporters, likely reflecting—at least in thereductions
latter—a reactive feedback inhibition; this probably contributes to the diminished 2-deoxyglucose
accumulation in both disorders.  2) Excitotoxicity is more likely to be a consequence of glucose
deprivation; this is a well-established relationship , whereas the claim that high glucose elevates
glutamate release is tenuous and unsupported by citations.  Publications documenting a diminution
of GLUT1 levels in hyperglycemia and/or the converse, an elevation in hypoglycemia, comprise an
overwhelming body of evidence .  The authors later provide some evidence suggesting effects
on the BBB from metabolic abnormalities in rat models, particularly those brought on by diet, but
data in humans is spotty and of unclear relevance to glucose delivery.”
 
: We agree with the reviewer and have reorganized the section on “Mechanisms linkingResponse
diabetes to dementia (p. 3)” and have modified discussion of the relationship between peripheral
hyperglycemia and CNS hyperglycemia, GLUT1 glucose transporter, and excitotoxicity in
response to the reviewer’s feedback. Specifically, we have indicated that excitotoxicity in the brain
may be more closely related to glucose deprivation via reductions in endothelial glucose
transporters.
The following text can be found on p. 4, paragraph 3: “Chronic hyperglycemia has been associated
with reductions in endothelial glucose transporters such as GLUT1 that could lead to glucose
deprivation and excitotoxicity, and could account for some of the neurocognitive complications of
diabetes (Gjedde and Crone 1981; Matthaei et al. 1986). This is unlike diabetic retinopathy, which
has been associated with upregulation of GLUT1 glucose transporter ( ) and isKumagai , 1996et al.
another example of how diabetic complications in the brain may differ from other organ systems.”
 
: Point 3 "Unlike other complications of diabetes…, neurocognitive complications of diabetes have
not clearly been demonstrated to correlate with measures of peripheral glycemia (with the
exception of very poor glycemic control, HbA1c > 10% and a potential role for glycemic variability)
and there is only limited evidence for a modest association with other measures of peripheral
glucose regulation…."
 
“Why would it be necessary—or indeed, even helpful—to exclude HbA1c levels and glycemic
control from the calculus?  Which indices of peripheral glycemia would be more justifiable?  To be
sure, 10% is a quite high level for HbA1c, but lower levels might show a detectable effect in an
adequately powered study.  Moreover, HbA1c might not change dramatically under conditions of
highly fluctuating blood-glucose concentrations, and yet such wild swings could easily produce
intolerable strains on glucose-sensitive tissues—including brain endothelium—simply by virtue of
their volatility.”
 
: We appreciate the need for clarification on this comment. We did not intend to suggestResponse
that HbA1c or glycemic variability were unimportant, and we agree that some existing studies may
be underpowered to detect effects at lower levels of hyperglycemia (i.e., HbA1c < 10%). We have
modified our text to emphasize future studies should not ignore the roles of HbA1c and glycemic
3,4
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modified our text to emphasize future studies should not ignore the roles of HbA1c and glycemic
variability, and there is a need for more adequately powered studies to clarify the roles for these
variables in cognitive impairment and dementia. The following text can be found on p. 5, paragraph
2: “It is possible that lower levels of hyperglycemia (i.e., HbA1c < 10%) may have detectable
effects on neurocognitive function in adequately powered studies or that HbA1c levels may not
reflect highly fluctuating blood glucose concentrations, which could have independent deleterious
effects on glucose-sensitive tissues such as brain endothelium.”
 
: “The authors are to be applauded for their mention (however brief) of the apparent paradoxPoint 4
between the ill effects of pathological insulin resistance versus the benefits of experimentally
interrupting insulin signaling, at least in .  It should be noted that similar benefits (e.g., onC. elegans
live span) accrue in mammals from inhibition of signaling for insulin-like growth factor (IGF), and C.
 have only one peptide to accomplish the roles of both insulin and IGF.  Nevertheless, theelegans
conundrum is one that has vexed experimental gerontologists for decades, owing in part to the
similar benefits afforded by attention of the insulin/IGF signaling (IIS) pathway and by dietary
restriction, the latter of which certainly reduces overall insulin production.  One should not expect
the authors to have cracked this tough nut, but important rumination might result from a slightly
more complete discussion of the differences between reactive (feedback-mediated) insulin
resistance and the proactive sort effected by empirical manipulation of IIS.” 
 
: We appreciate this important point from the reviewer; however, this did not needResponse
receive substantial discussion at the workshop and, given the complexity of this issue, would
require substantial more attention beyond the scope of the current paper. We have acknowledged
this point in the manuscript. The following text can be found on p.5, paragraph 2: “The apparent
paradox between pathological insulin resistance and the benefits of acute disruption of insulin
signaling is a complex topic requiring further research attention.”
 
: “Also given short shrift here is the undeniable connection of inflammation to both metabolicPoint 5
syndrome and neurocognitive disorders.  This is obviously an underappreciated link that deserves
greater attention among scientists seeking to synthesize these fields; reviewers of grants and
papers continue to express befuddlement when the topic of neuroinflammation is broached in this
context.  Given the overwhelming evidence for inflammation-related events in the etiologies of both
T2DM and AD, it is almost certain to contribute to their coincidence.  In fact, compelling evidence
has supported just this sort of causal involvement in animal models .  The authors have included
the word “inflammation,” distributed diffusely in the paper; perhaps it would create the appropriate
emphasis if some of these references were consolidated in one or two paragraphs along with more
specific information, e.g., the seminal role of IKK2 in insulin resistance  and Aβ effects .”
 
: We agree with the reviewer that this is another important area for further researchResponse
attention. However, inflammation in the context of diabetes and dementia was not the primary
focus of the workshop; therefore, we refer the reader to recent reviews for more in depth attention
to this important topic. The following text can be found on p.5, paragraph 1: “Inflammation-related
events in the periphery and brain may be another important factor explaining the connection
between diabetes and neurocognitive dysfunction (see (Ferreira et al. 2014; De Felice and
Lourenco 2015) for recent reviews of this topic).”
 
: “Finally, the paper’s conclusion with “Some broad research needs” is doubtlessly faithful toPoint 6
the output of the workshop’s deliberations, but many of the points outlined in this list come across
as rather vague.  Without further elaboration, it is not clear what gaps in knowledge some of them
would address.  One wonders if several could be combined and embellished with a bit more
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would address.  One wonders if several could be combined and embellished with a bit more
elaboration.”
 
: We apologize for being overly vague in this section and have revised this section toResponse
provide more clarity. 
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